Ambulatory use of blinatumomab in paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia at a single centre in South Africa
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with B-ALL comprising approximately 85% of all cases. Despite a high cure rate, those with refractory disease and/or relapsed (R/R) B-ALL have an inferior overall survival. Blinatumomab, a novel therapy, is a bispecific cluster...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
AOSIS
2026-05-01
|
| Ráidu: | South African Journal of Oncology |
| Fáttát: | |
| Liŋkkat: | https://sajo.org.za/index.php/sajo/article/view/365 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|